Tuberculosis MDR-TB & XDR-TB The 2008 Report
The Trends and Developments report presents a top-level overview of the drug phenomenon in Europe, covering drug supply, use and public health problems as well as drug policy and responses. Together with the online Statistical Bulletin and 30 Country Drug Reports, it makes up the 2019 European Drug ...Report package.
Available in different languages: http://www.emcdda.europa.eu/publications/edr/trends-developments/2019_en
more
Antimicrobial resistance (AMR) is an increasing worldwide public health problem with
important implications for the European Union (EU). When antibiotics become
ineffective, bacterial infections lead to increased morbidity, use of healthcare,
mortality and cost. Globally, estimates suggest that ...AMR leads to 700 000 deaths
per annum. For the EU, the European Centre for Disease Prevention and Control
(ECDC) has estimated that AMR currently causes 25 000 deaths annually and losses of
at least EUR 1.5 billion per annum in extra healthcare costs and productivity.
more
Table of contents:
- Preface
- Introductory note and acknowledgements
- Commentary
- Chapter 1: Drug supply and the market
- Chapter 2: Drug use prevalence and trends
- Chapter 3: Drug-related harms and responses
- Annex: National data tables
Available in 24 languages on:
http://www.emcdd...a.europa.eu/publications/edr/trends-developments/2018
more
Sources: National Commitment and Policy Instrument, 2019
Eurosurveillance
Impact Factor 5.7
June 2015
www.eurosurveillance.org
Featuring a series of articles on HIV and STI epidemiology, prevention and control among MSM in Europe
2nd revised edition. Accessed Apri. 17, 2019
Prevention strategies based on scientific evidence working with families, schools, and communities can ensure that children and youth, especially the most marginalized and poor, grow and stay healthy and safe into adulthood and old age. For every dollar ...spent on prevention, at least ten can be saved in future health, social and crime costs.
more
10 years after the UN general assembly special session on drugs
An essential resource that helps a community understand, treat, and prevent many health problems that affect women. Topics include reproductive health, violence, mental health, HIV, and more.
Rapid review and case studies from Member States
Этот документ содержит техническое руководство для стран по мониторингу усилий, направленных на
профилактику и лечение ВИЧ-инфекции среди людей, употребляющих и...ъекционные наркотики (ЛУИН),
и определению амбициозных, но достижимых задач национального уровня для расширения всеобщего
доступа к услугам.
more
В настоящем кратком докладе анализируются последние данные о распространенности употребления
табака в Европейском регионе ВОЗ, взятые из доклада о глобальной та...бачной эпидемии за 2017 г., рассматриваются предшествующие аналогичные доклады начиная с 2008 г, а также достижения в деле реализации комплекса мер MPOWER в Европейском регионе. В качестве обоснования используются фактические данные, собранные в «Сборнике аргументов для борьбы против табака». Оценивается прогресс, достигнутый в Европейском регионе ВОЗ в реализации Дорожной карты действий с целью усиления мер по осуществлению Рамочной конвенции ВОЗ по борьбе против табака в Европейском регионе на 2015–2025 гг. (далее – Дорожная карта), и протяженность дальнейшего пути к достижению конечной цели.
more
Patients with diabetes are at increased risk of developing cardiovascular disease (CVD) with its manifestations of coronary artery disease (CAD), heart failure (HF), atrial fibrillation (AF), and stroke, as well as aortic and peripheral artery diseases. In addition, diabetes is a major risk factor f...or developing chronic kidney disease (CKD), which in itself is associated with developing CVD. The combination of diabetes with these cardio-renal comorbidities enhances the risk not only for cardiovascular (CV) events but also for CV and all-cause mortality. The current European Society of Cardiology (ESC) Guidelines on the management of cardiovascular disease in patients with diabetes are designed to guide prevention and management of the manifestations of CVD in patients with diabetes based on data published until end of January 2023. Over the last decade, the results of various large cardiovascular outcome trials (CVOTs) in patients with diabetes at high CV risk with novel glucose- lowering agents, such as sodium–glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), but also novel non-steroidal mineralocorticoid receptor antagonists (MRAs), such as finerenone have substantially expanded available therapeutic op-
tions, leading to numerous evidence-based recommendations for the management of this patient population.
more